viewCollagen Solutions PLC

ChondroMimetic® Update

/**/ h1{margin:0cm;margin-bottom:.0001pt;text-align:justify;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h2{margin:0cm;margin-bottom:.0001pt;text-align:justify;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:bold;font-div:italic;}h3{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:21.3pt;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:bold;font-div:italic;}h4{margin:0cm;margin-bottom:.0001pt;text-align:right;font-size:10.5pt;font-family:"Times New Roman","serif";font-weight:normal;font-div:italic;}h5{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:21.3pt;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h6{margin:0cm;margin-bottom:.0001pt;text-align:justify;font-size:10.5pt;font-family:"Times New Roman","serif";font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #0563C1 } visited{ color: #954F72 } .de{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.de{}p.ec{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: center}span.ea{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.ed{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold}span.dy{font-size:11.0pt;font-family: "Calibri","sans-serif"}p.ee{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: justify}p.ef{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify}span.dv{font-size:11.0pt; font-family:"Calibri","sans-serif"}span.dt{font-size:11.5pt;font-family:"Segoe UI","sans-serif"; color:#212121;background:white} p.eg{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:#00000A;font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify}span.ds{color:windowtext}table.eh{width:474.65pt;margin-left:-5.4pt;border-collapse:collapse}td.dp{width:225.9pt;padding:0cm 5.4pt 0cm 5.4pt}p.ei{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:#00000A;font-weight: bold; line-height: normal; margin-bottom: 0cm}td.dn{width:227.15pt; padding:0cm 5.4pt 0cm 5.4pt}p.ej{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:#00000A;margin-bottom:0cm;margin-bottom:.0001pt; line-height:normal}p.ek{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:#00000A;line-height: normal; margin-bottom: 0cm; text-align: right}td.dl{width:249.95pt; padding:0cm 5.4pt 0cm 5.4pt}td.dk{width:203.1pt;padding:0cm 5.4pt 0cm 5.4pt} td.dj{width:237.65pt; padding:0cm 5.4pt 0cm 5.4pt}td.di{width:215.4pt; padding:0cm 5.4pt 0cm 5.4pt}span.dh{color:#0070C0}td.dg{border:none} /**/
RNS Number : 5866O
Collagen Solutions PLC
31 January 2019


31 January 2019


Collagen Solutions plc

("Collagen Solutions", the "Company" or the "Group")


ChondroMimetic® Update

Distribution Agreement with Indonesian Partner and Update on CE Mark Process


Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that it has entered into a new license and distribution agreement for ChondroMimetic® with an Indonesian partner, PT Rajawali Mutiara Sejahtera ("Rajawali Medika"). Rajawali Medika will collaborate with Collagen Solutions to obtain regulatory approval and launch ChondroMimetic® in Indonesia with the potential to expand to several other South East Asian countries.  Financial terms of the agreement were not disclosed.


Rajawali Medika, based in Jakarta, was founded and managed by highly experienced professionals in sales and marketing of medical devices in the Asia Pacific region. The team's prior experience includes successful hands-on sales and marketing of sports medicine and arthroscopy products with J&J's DePuy Mitek division. Rajawali Medika has a strong network of key orthopaedic surgeons and sales distribution channels in South East Asian countries, experience in conducting professional education programmes and workshops, as well as experience in regulatory affairs to achieve speed to market.


ChondroMimetic® is a minimally-invasive surgically placed scaffold for the repair of cartilage defects in the knee, backed by positive results of an eight-year clinical extension study reported in Q1 2018.  The Company has made a submission for a CE Mark for ChondroMimetic® and is currently awaiting further feedback from the Notified Body reviewing the submission. The timing of the CE Mark approval is subject to a due process to be undertaken by the Regulatory Authority, and the previously stated timing of approval by the fiscal year end is therefore uncertain. ChondroMimetic® is not currently approved for sale in any markets.


Jamal Rushdy, CEO, commented: "We are pleased to enter the partnership agreement with Rajawali Medika for Chondromimetic in South East Asia. We will benefit enormously from both their in-depth expertise in the area of sports medicine procedures as well as their regional presence. This agreement adds to other distributor agreements that we have been putting in place in Asia and Europe in order to initiate our launch of Chondromimetic soon after we obtain regulatory approval. We are currently awaiting feedback regarding our CE Mark submission and we will provide an update once new information becomes available and certainly no later than our proposed April trading update."



Collagen Solutions Plc


Jamal Rushdy, CEO 

Via Walbrook

Hilary Spence, CFO




Cenkos Securities Plc (Nominated Adviser and Broker)


Steve Cox (Corporate Finance)

Tel: 0207 397 8900

Giles Balleny




Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected] 

Anna Dunphy

Mob: 07876 741 001

Helen Cresswell

Mob: 07841 917 679


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Collagen Solutions PLC

Price: 3.55

Market: LSE
Market Cap: £15.75 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Collagen Solutions released financial number showing more...

Collagen Solutions (LON: COS) CEO Jamal Rushdy joined Steve Darling from Proactive to discuss the company releasing their financial numbers that show impressive double-digit sales growth.  Rushdy talks about the numbers and also their tissue division that continues to be a revenue driver.

3 weeks ago